CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Macular Degeneration codes

5 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment J2777 Injection, faricimab-svoa, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 105.92M services · est. ▲ 64.7% YoY · 190,649 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 53.01M observed fee-for-service services

See the national market for J2777 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0178 Injection, aflibercept, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.45M services · est. ▼ 18.1% YoY · 315,602 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.69M observed fee-for-service services

See the national market for J0178 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0177 Injection, aflibercept hd, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 3.59M services · est. · 65,417 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.82M observed fee-for-service services

See the national market for J0177 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2782 Injection, avacincaptad pegol, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 2.93M services · est. · 15,948 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.43M observed fee-for-service services

See the national market for J2782 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0179 Injection, brolucizumab-dbll, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 32,805 services · est. ▼ 47.7% YoY · 658 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 16,727 observed fee-for-service services

See the national market for J0179 → ranked groups · states · 12-yr trend